Nephrotoxicity of ciclosporin A: Short-term gain, long-term pain?

Nephrology Dialysis Transplantation

Volumn 21, Issue 8, 2006, Pages 2060-2063

  Chapman, Jeremy R ^a   Nankivell, Brian J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chronic allograft nephropathy; Ciclosporin; Nephrotoxicity

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE TOXICITY; ANEMIA; CHRONIC TOXICITY; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG WITHDRAWAL; FIBROMATOSIS; FIBROSING ALVEOLITIS; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY CALCIFICATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; NEPHROTOXICITY; NOTE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; TREATMENT PLANNING; WOUND HEALING IMPAIRMENT;

ACUTE DISEASE; CHRONIC DISEASE; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; TACROLIMUS;

EID: 33748081967     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl219     Document Type: Note

References (31)

1. Calne RY, White DJ, Thiru S et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323-1327
2. Calne RY, Rolles K, White DJ et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2: 1033-1036
3. Morris PJ, Chapman JR, Allen RD et al. Cyclosporin conversion versus conventional immunosuppression: Long term follow up and histological evaluation. Lancet 1987; 2: 586-591
4. Hall BM, Tiller DJ, Hardie I et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: Long term cyclosporine, short term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988; 318: 1499-1507
5. Slapak M, Geoghegan T, Digard N, Ahmed K, Sharman VL, Crockett R. The use of low-dose cyclosporine A in combination with azathioprine and steroids in renal transplantation. Transplant Proc 1987; 19 [2 Suppl 2]: 41-45
6. Mihatsch MI, Theil G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20 [3 Suppl 3]: 759
7. Chapman JR, Griffiths D, Harding N, Morris PJ. The reversibility of cyclosporin nephrotoxicity after three months treatment. Lancet 1985; 1: 128-130
8. European multicentre trial of cyclosporine in renal transplantation: Ten year follow-up. Transplant Proc 1993; 25 [1pt 1]: 527
9. Hollander AA, van Saase JL, Kootte AM et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610-614
10. Solez K, Vincenti F, Filo RS. Histopathology findings from 2 year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736-1740
11. Mathew TH, McDonald SP, Russ GR. Renal transplant outcome beyond five years. Effect of donor and recipient factors and immunosuppression. ANZDATA Registry Report 2001, 112-115. Australia and New Zealand Dialysis and Transplant Registry. Adelaide South Australia
12. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J. Australian Multicenter Trial of Cyclosporine Withdrawal Study Group and the ANZ Dialysis and Transplantation Registry. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653-1660
13. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1995; 55: 713-723
14. Nankivell BJ, Fenton-Lee CA, Kuypers DRJ et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515-523
15. Nankivell BJ, Borrows RJ, O'Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. New Engl J Med 2003; 349: 2326-2333
16. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Allen RDM, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242-249
17. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Chapman JR, Allen RDM. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565
18. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Chapman JR, Allen RDM. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004; 78: 434-441
19. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Allen RDM, Chapman JR. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004; 78: 557-565
20. Myers BB, Newton L. Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrology 1991; 2 [Suppl 1]: S45-S52
21. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026
22. Mihatsch MI, Ryfell B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995; 52: S63-S69
23. Kahan BD, Camardo JS. Rapamycin: Clinical results and future opportunities. Transplantation 2001; 72: 1181-1193
24. Vitko S, Margreiter R, Weimar W et al. RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521-2530
25. Podder H, Stepkowski SM, Napoli KL et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059-1071
26. Mota A, Arias M, Taskinen EI et al. Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-961
27. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917
28. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748-1755
29. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076
30. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009-3014
31. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522